Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EpCAM CAR T-cells
- Development stage
- Unknown
- Lead developer
- Immunofoco
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intraperitoneal, Intravenous
01
Overview
EpCAM CAR T-cells are chimeric antigen receptor (CAR) T-cell therapies engineered to target Epithelial Cell Adhesion Molecule (EpCAM), a cell-surface glycoprotein highly expressed in various epithelial cancers, including gastric, colorectal, ovarian, and breast cancers. These autologous or allogeneic T-cells are genetically modified to express a CAR consisting of an anti-EpCAM single-chain variable fragment (scFv) linked to intracellular signaling domains (such as CD3ζ and costimulatory domains like CD28, 4-1BB, or Dectin-1). Upon binding to EpCAM on tumor cells, the CAR T-cells are activated to proliferate, secrete cytokines, and exert direct cytotoxic activity against the target cancer cells. EpCAM CAR T-cells are being evaluated in preclinical and early-phase clinical trials for the treatment of EpCAM-positive solid tumors.
- Other names
- EpCAM CAR-TEpCAM CAR-T cellsEpCAM-targeting CAR-T cellsanti-EpCAM CAR-T cells
02
Targets
TNFRSF9 (CD137 extracellular domain)CD28 (Cluster of Differentiation 28)CD3 (T-cell surface glycoprotein CD3)CLEC7A (Dectin-1)EPCAM (Epithelial cell adhesion molecule)
Beyond the preview
Go deeper on EpCAM CAR T-cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EpCAM CAR T-cells.